The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection

Current HIV/AIDS Reports

Volumn 14, Issue 6, 2017, Pages 211-219

  Lake, Jordan E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Antiretroviral therapy; HIV; Lipohypertrophy; Obesity; Visceral fat

Indexed keywords

BODY MASS; CARDIOVASCULAR DISEASE; COGNITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF QUANTITATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; SEX DIFFERENCE; VISCERAL ADIPOSITY; BODY WEIGHT GAIN; COGNITIVE DEFECT; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INTRA-ABDOMINAL FAT; PATHOPHYSIOLOGY;

ADIPOSITY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; COGNITIVE DYSFUNCTION; HIV INFECTIONS; HUMANS; INTRA-ABDOMINAL FAT; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; WEIGHT GAIN;

EID: 85031499112     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-017-0368-6     Document Type: Review

References (110)

1. Hamdy OUG, Oral EA Obesity practice essentials. Medscape. 2016.
2. Study of Fat Redistribution and Metabolic Change in HIV Infection. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006;42(5):562–71. https://doi.org/10.1097/01.qai.0000229996.75116.da.
3. Brown TT, Xu X, John M, Singh J, Kingsley LA, Palella FJ, et al. Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther. 2009;6:8. https://doi.org/10.1186/1742-6405-6-8.
4. Joy T, Keogh HM, Hadigan C, Dolan SE, Fitch K, Liebau J, et al. Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. J Acquir Immune Defic Syndr. 2008;47(2):174–84. https://doi.org/10.1097/QAI.0b013e31815b0792.
5. Buchacz K, Baker RK, Palella FJ Jr, Shaw L, Patel P, Lichtenstein KA, et al. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 2013;18(1):65–75. https://doi.org/10.3851/IMP2450.
6. Levy ME, Greenberg AE, Hart R, Powers Happ L, Hadigan C, Castel A, et al. High burden of metabolic comorbidities in a citywide cohort of HIV outpatients: evolving health care needs of people aging with HIV in Washington, DC. HIV Med. 2017; https://doi.org/10.1111/hiv.12516.
7. Hernandez D, Kalichman S, Cherry C, Kalichman M, Washington C, Grebler T. Dietary intake and overweight and obesity among persons living with HIV in Atlanta Georgia. AIDS Care. 2017;29(6):767–71. https://doi.org/10.1080/09540121.2016.1238441.
8. Erlandson KM, Taejaroenkul S, Smeaton L, Gupta A, Singini IL, Lama JR, et al. A randomized comparison of anthropomorphic changes with preferred and alternative Efavirenz-based antiretroviral regimens in diverse multinational settings. Open Forum Infect Dis. 2015;2(3):ofv095. https://doi.org/10.1093/ofid/ofv095.
9. Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016;17(4):255–68. https://doi.org/10.1111/hiv.12294.
10. Lakey W, Yang LY, Yancy W, Chow SC, Hicks C. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retrovir. 2013;29(3):435–40. https://doi.org/10.1089/AID.2012.0234.
11. • McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dube MP, et al. Body composition changes after initiation of Raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis. 2016;62(7):853–62. https://doi.org/10.1093/cid/ciw017. A well-designed, head-to-head comparison of the metabolic effects of modern protease inhibitor- vs integrase strand transfer inhibitor-based ART.
12. Mave V, Erlandson KM, Gupte N, Balagopal A, Asmuth DM, Campbell TB, et al. Inflammation and change in body weight with antiretroviral therapy initiation in a multinational cohort of HIV-infected adults. J Infect Dis. 2016;214(1):65–72. https://doi.org/10.1093/infdis/jiw096.
13. Yuh B, Tate J, Butt AA, Crothers K, Freiberg M, Leaf D, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015;60(12):1852–9. https://doi.org/10.1093/cid/civ192.
14. Kim DJ, Westfall AO, Chamot E, Willig AL, Mugavero MJ, Ritchie C, et al. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr. 2012;61(5):600–5. https://doi.org/10.1097/QAI.0b013e31827303d5.
15. • Grant PM, Kitch D, McComsey GA, Collier AC, Bartali B, Koletar SL, et al. Long-term body composition changes in antiretroviral-treated HIV-infected individuals. AIDS. 2016;30(18):2805–13. https://doi.org/10.1097/QAD.0000000000001248. The longest published follow-up of body composiiton changes following ART initiation in HIV-infected persons, with comparison to an HIV-uninfected control group.
16. Bhagwat P, Ofotokun I, McComsey GA, Brown TT, Moser C, Sugar CA, et al. Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes. Antivir Ther. 2017; https://doi.org/10.3851/IMP3148.
17. Bhagwat POI, McComsey GA, Brown TT, Moser C, Sugar CA, Currier JS. Raltegravir is associated with greater abdominal fat increases after antiretroviral therapy initiation compared to protease inhibitors. Abstracts from the 18th International Workshop of Co-morbidities and Adverse Drug Reactions in HIV. 2016.
18. Shah RV, Murthy VL, Abbasi SA, Blankstein R, Kwong RY, Goldfine AB, et al. Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA Study. JACC Cardiovasc Imaging. 2014;7(12):1221–35. https://doi.org/10.1016/j.jcmg.2014.07.017.
19. Scherzer R, Heymsfield SB, Lee D, Powderly WG, Tien PC, Bacchetti P, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS. 2011;25(11):1405–14. https://doi.org/10.1097/QAD.0b013e32834884e6.
20. Lynch LA, O'Connell JM, Kwasnik AK, Cawood TJ, O'Farrelly C, O'Shea DB. Are natural killer cells protecting the metabolically healthy obese patient? Obesity (Silver Spring). 2009;17(3):601–5. https://doi.org/10.1038/oby.2008.565.
21. Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EA, et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab. 2001;86(3):1020–5. https://doi.org/10.1210/jcem.86.3.7365.
22. Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab. 2013;98(10):E1610–9. https://doi.org/10.1210/jc.2013-2038.
23. Pujia A, Gazzaruso C, Ferro Y, Mazza E, Maurotti S, Russo C et al. Individuals with metabolically healthy overweight/obesity have higher fat utilization than metabolically unhealthy individuals. Nutrients. 2016;8(1). doi:https://doi.org/10.3390/nu8010002.
24. Yoon JW, Jung CH, Kim MK, Park HE, Park KS, Jang HC, et al. Influence of the definition of “metabolically healthy obesity” on the progression of coronary artery calcification. PLoS One. 2017;12(6):e0178741. https://doi.org/10.1371/journal.pone.0178741.
25. Zheng R, Liu C, Wang C, Zhou B, Liu Y, Pan F, et al. Natural course of metabolically healthy overweight/obese subjects and the impact of weight change. Nutrients. 2016;8(7):430. https://doi.org/10.3390/nu8070430.
26. Lake JE LX, Palella FJ, Erlandson K, Wiley D, Kingsley L, Jacobson LP, Brown TT. Metabolic health across the body mass index spectrum in HIV-infected and HIV-uninfected men. Abstracts from the 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. 2015.
27. Bourlier V, Sengenes C, Zakaroff-Girard A, Decaunes P, Wdziekonski B, Galitzky J, et al. TGFbeta family members are key mediators in the induction of myofibroblast phenotype of human adipose tissue progenitor cells by macrophages. PLoS One. 2012;7(2):e31274. https://doi.org/10.1371/journal.pone.0031274.
28. Haase J, Weyer U, Immig K, Kloting N, Bluher M, Eilers J, et al. Local proliferation of macrophages in adipose tissue during obesity-induced inflammation. Diabetologia. 2014;57(3):562–71. https://doi.org/10.1007/s00125-013-3139-y.
29. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17(2):179–88. https://doi.org/10.1038/nm.2279.
30. Brestoff JR, Artis D. Immune regulation of metabolic homeostasis in health and disease. Cell. 2015;161(1):146–60. https://doi.org/10.1016/j.cell.2015.02.022.
31. Hong KM, Burdick MD, Phillips RJ, Heber D, Strieter RM. Characterization of human fibrocytes as circulating adipocyte progenitors and the formation of human adipose tissue in SCID mice. FASEB J. 2005;19(14):2029–31. https://doi.org/10.1096/fj.05-4295fje.
32. Divoux A, Tordjman J, Lacasa D, Veyrie N, Hugol D, Aissat A, et al. Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes. 2010;59(11):2817–25. https://doi.org/10.2337/db10-0585.
33. Gaggini M, Saponaro C, Gastaldelli A. Not all fats are created equal: adipose vs. ectopic fat, implication in cardiometabolic diseases. Horm Mol Biol Clin Investig. 2015;22(1):7–18. https://doi.org/10.1515/hmbci-2015-0006.
34. Giralt M, Domingo P, Villarroya F. Adipose tissue biology and HIV-infection. Best Pract Res Clin Endocrinol Metab. 2011;25(3):487–99. https://doi.org/10.1016/j.beem.2010.12.001.
35. Lim S, Meigs JB. Links between ectopic fat and vascular disease in humans. Arterioscler Thromb Vasc Biol. 2014;34(9):1820–6. https://doi.org/10.1161/ATVBAHA.114.303035.
36. Orlando G, Guaraldi G, Zona S, Carli F, Bagni P, Menozzi M, et al. Ectopic fat is linked to prior cardiovascular events in men with HIV. J Acquir Immune Defic Syndr. 2012;59(5):494–7. https://doi.org/10.1097/QAI.0b013e31824c8397.
37. Koethe JR, Hulgan T, Niswender K. Adipose tissue and immune function: a review of evidence relevant to HIV infection. J Infect Dis. 2013;208(8):1194–201. https://doi.org/10.1093/infdis/jit324.
38. de Souza Dantas Oliveira SH, de Souza Aarao TL, da Silva Barbosa L, Souza Lisboa PG, Tavares Dutra CD, Margalho Sousa L, et al. Immunohistochemical analysis of the expression of TNF-alpha, TGF-beta, and caspase-3 in subcutaneous tissue of patients with HIV lipodystrophy syndrome. Microb Pathog. 2014;67-68:41–7. https://doi.org/10.1016/j.micpath.2014.02.004.
39. Utay NS KD, Fichtenbaum C, Lederman MM, Estes JD, Magyar C, Klingman KL, Currier JS, Lake JE. Telmisartan does not improve lymph node or fat fibrosis in treated HIV infection. Abstracts from the 2017 Conference on Retroviruses and Opportunistic Infections. 2017.
40. •• Damouche A, Lazure T, Avettand-Fenoel V, Huot N, Dejucq-Rainsford N, Satie AP, et al. Adipose tissue is a neglected viral reservoir and an inflammatory site during chronic HIV and SIV infection. PLoS Pathog. 2015;11(9):e1005153. https://doi.org/10.1371/journal.ppat.1005153. A landmark paper identifying adipose tisue as a potential reservoir for HIV infection.
41. • Agarwal N, Balasubramanyam A. Viral mechanisms of adipose dysfunction: lessons from HIV-1 Vpr. Adipocyte. 2015;4(1):55–9. https://doi.org/10.4161/adip.29852. Outlines an animal model important to our understanding of HIV-specific effects on adipose tissue.
42. •• Couturier J, Suliburk JW, Brown JM, Luke DJ, Agarwal N, Yu X, et al. Human adipose tissue as a reservoir for memory CD4+ T cells and HIV. AIDS. 2015;29(6):667–74. https://doi.org/10.1097/QAD.0000000000000599. The second landmark paper identifying adipose tisue as a potential reservoir for HIV infection.
43. Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology. 2008;135(1):226–33. https://doi.org/10.1053/j.gastro.2008.03.022.
44. Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol. 2014;20(44):16452–63. https://doi.org/10.3748/wjg.v20.i44.16452.
45. Masia M, Padilla S, Alvarez D, Lopez JC, Santos I, Soriano V, et al. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy. AIDS. 2013;27(2):181–9. https://doi.org/10.1097/QAD.0b013e32835a1156.
46. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med. 2013;14(4):195–207. https://doi.org/10.1111/j.1468-1293.2012.01051.x.
47. Conley LJ, Bush TJ, Rupert AW, Sereti I, Patel P, Brooks JT, et al. Obesity is associated with greater inflammation and monocyte activation among HIV-infected adults receiving antiretroviral therapy. AIDS. 2015;29(16):2201–7. https://doi.org/10.1097/QAD.0000000000000817.
48. Bonamichi B, Lee J. Unusual suspects in the development of obesity-induced inflammation and insulin resistance: NK cells, iNKT cells, and ILCs. Diabetes Metab J. 2017;
49. Stambullian M, Feliu MS, Cassetti LI, Slobodianik NH. Nutritional status and lipid profile in HIV-infected adults. Endocr Metab Immune Disord Drug Targets. 2015;15(4):302–7.
50. Hulgan T, Boger MS, Liao DH, McComsey GA, Wanke CA, Mangili A, et al. Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial. Mediat Inflamm. 2014;2014:803095. https://doi.org/10.1155/2014/803095.
51. Vidal F, Domingo P, Villarroya F, Giralt M, Lopez-Dupla M, Gutierrez M, et al. Adipogenic/lipid, inflammatory, and mitochondrial parameters in subcutaneous adipose tissue of untreated HIV-1-infected long-term nonprogressors: significant alterations despite low viral burden. J Acquir Immune Defic Syndr. 2012;61(2):131–7. https://doi.org/10.1097/QAI.0b013e31825c3a68.
52. Diaz-Delfin J, Domingo P, Wabitsch M, Giralt M, Villarroya F. HIV-1 Tat protein impairs adipogenesis and induces the expression and secretion of proinflammatory cytokines in human SGBS adipocytes. Antivir Ther. 2012;17(3):529–40. https://doi.org/10.3851/IMP2021.
53. Guaraldi G, Luzi K, Bellistri GM, Zona S, Domingues da Silva AR, Bai F, et al. CD8 T-cell activation is associated with lipodystrophy and visceral fat accumulation in antiretroviral therapy-treated virologically suppressed HIV-infected patients. J Acquir Immune Defic Syndr. 2013;64(4):360–6. https://doi.org/10.1097/QAI.0000000000000001.
54. Srinivasa S, Fitch KV, Wong K, Torriani M, Mayhew C, Stanley T, et al. RAAS activation is associated with visceral adiposity and insulin resistance among HIV-infected patients. J Clin Endocrinol Metab. 2015;100(8):2873–82. https://doi.org/10.1210/jc.2015-1461.
55. Boccara F, Auclair M, Cohen A, Lefevre C, Prot M, Bastard JP, et al. HIV protease inhibitors activate the adipocyte renin angiotensin system. Antivir Ther. 2010;15(3):363–75. https://doi.org/10.3851/IMP1533.
56. • Srinivasa S, Fitch KV, Wong K, Torriani M, Mayhew C, Stanley T et al. RAAS activation is associated with visceral adiposity and insulin resistance among HIV-infected patients. J Clin Endocrinol Metab. 2015:jc20151461. doi:https://doi.org/10.1210/jc.2015-1461. This study represents an important step in our understanding of the relationship between renin-angiotensin system activation, visceral adiposity and its sequelae in HIV infection.
57. Gerard P. Gut microbiota and obesity. Cell Mol Life Sci. 2016;73(1):147–62. https://doi.org/10.1007/s00018-015-2061-5.
58. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab. 2001;86(2):504–10. https://doi.org/10.1210/jcem.86.2.7175.
59. Tchkonia T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scrable H, et al. Fat tissue, aging, and cellular senescence. Aging Cell. 2010;9(5):667–84. https://doi.org/10.1111/j.1474-9726.2010.00608.x.
60. Freitas P, Carvalho D, Santos AC, Madureira AJ, Martinez E, Pereira J, et al. Adipokines, hormones related to body composition, and insulin resistance in HIV fat redistribution syndrome. BMC Infect Dis. 2014;14:347. https://doi.org/10.1186/1471-2334-14-347.
61. Palella FJ Jr, McKibben R, Post WS, Li X, Budoff M, Kingsley L, et al. Anatomic fat depots and coronary plaque among human immunodeficiency virus-infected and uninfected men in the Multicenter AIDS Cohort Study. Open Forum Infect Dis. 2016;3(2):ofw098. https://doi.org/10.1093/ofid/ofw098.
62. Samaras K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr HIV/AIDS Rep. 2012;9(3):206–17. https://doi.org/10.1007/s11904-012-0124-x.
63. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec’s public health insurance database. J Acquir Immune Defic Syndr. 2011;57(3):245–53. https://doi.org/10.1097/QAI.0b013e31821d33a5.
64. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13(8):453–68. https://doi.org/10.1111/j.1468-1293.2012.00996.x.
65. Koethe JR, Grome H, Jenkins CA, Kalams SA, Sterling TR. The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy. AIDS. 2016;30(1):83–91. https://doi.org/10.1097/QAD.0000000000000893.
66. Seang SKT, Currier JS, Lake JE. Endothelial progenitor cell production is suppressed and associated with systemic inflammation and monocyte activation in older HIV-infected men. Abstracts from IDWeek 2016. 2016.
67. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008;47(2):250–7. https://doi.org/10.1086/589294.
68. Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50(5):464–73. https://doi.org/10.1097/QAI.0b013e318198a88a.
69. Hadigan C, Liebau J, Andersen R, Holalkere NS, Sahani DV. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr. 2007;46(3):312–7. https://doi.org/10.1097/QAI.0b013e3181568cc2.
70. Morse CG, McLaughlin M, Matthews L, Proschan M, Thomas F, Gharib AM, et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis. 2015;60(10):1569–78. https://doi.org/10.1093/cid/civ101.
71. Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28(Suppl 1):68–76. https://doi.org/10.1111/jgh.12212.
72. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50. https://doi.org/10.1056/NEJMra0912063.
73. Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, et al. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016;22(44):9674–93. https://doi.org/10.3748/wjg.v22.i44.9674.
74. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230(2):258–67. https://doi.org/10.1016/j.atherosclerosis.2013.07.052.
75. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;106(36):15430–5. https://doi.org/10.1073/pnas.0904944106.
76. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology. 2008;134(5):1369–75. https://doi.org/10.1053/j.gastro.2008.01.075.
77. Vallet-Pichard A, Mallet V, Pol S. Nonalcoholic fatty liver disease and HIV infection. Semin Liver Dis. 2012;32(2):158–66. https://doi.org/10.1055/s-0032-1316471.
78. Vodkin I, Valasek MA, Bettencourt R, Cachay E, Loomba R. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther. 2015;41(4):368–78. https://doi.org/10.1111/apt.13052.
79. Ghazarian M, Revelo XS, Nohr MK, Luck H, Zeng K, Lei H et al. Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome. Sci Immunol. 2017;2(10). doi:https://doi.org/10.1126/sciimmunol.aai7616.
80. Ray I, Mahata SK, De RK. Obesity: an immunometabolic perspective. Front Endocrinol (Lausanne). 2016;7:157. https://doi.org/10.3389/fendo.2016.00157.
81. Zanni MV, Schouten J, Grinspoon SK, Reiss P. Risk of coronary heart disease in patients with HIV infection. Nat Rev Cardiol. 2014;11(12):728–41. https://doi.org/10.1038/nrcardio.2014.167.
82. Matthews L, Kleiner DE, Chairez C, McManus M, Nettles MJ, Zemanick K, et al. Pioglitazone for hepatic steatosis in HIV/hepatitis C virus coinfection. AIDS Res Hum Retrovir. 2015;31(10):961–6. https://doi.org/10.1089/AID.2015.0093.
83. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–9. https://doi.org/10.1001/jama.2014.8334.
84. Tafesh ZH, Verna EC. Managing nonalcoholic fatty liver disease in patients living with HIV. Curr Opin Infect Dis. 2017;30(1):12–20. https://doi.org/10.1097/QCO.0000000000000344.
85. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Despres JP. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr. 1996;64(5):685–93.
86. Sattler FR, He J, Letendre S, Wilson C, Sanders C, Heaton R, et al. Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation. J Acquir Immune Defic Syndr. 2015;68(3):281–8. https://doi.org/10.1097/QAI.0000000000000458.
87. Okafor CN, Kelso NE, Bryant V, Burrell LE 2nd, Miguez MJ, Gongvatana A, et al. Body mass index, inflammatory biomarkers and neurocognitive impairment in HIV-infected persons. Psychol Health Med. 2017;22(3):289–302. https://doi.org/10.1080/13548506.2016.1199887.
88. Gustafson DR, Mielke MM, Keating SA, Holman S, Minkoff H, Crystal HA. Leptin, adiponectin and cognition in middle-aged HIV-infected and uninfected women. The Brooklyn women’s interagency HIV study. J Gerontol Geriatr Res. 2015;4(5) https://doi.org/10.4172/2167-7182.1000240.
89. • Lake JE, Popov M, Post WS, Palella FJ Jr, Sacktor N, Miller EN, et al. Visceral fat is associated with brain structure independent of human immunodeficiency virus infection status. J Neuro-Oncol. 2017;23(3):385–93. https://doi.org/10.1007/s13365-016-0507-7. This analysis of Multicenter AIDS Cohort participants documents increased VAT quantity as the clinical factor most strongly associated with brain atrophy, irrespective of HIV infection status.
90. Erlandson KM, Wu K, Koletar SL, Kalayjian RC, Ellis RJ, Taiwo B, et al. Association between frailty and components of the frailty phenotype with modifiable risk factors and antiretroviral therapy. J Infect Dis. 2017;215(6):933–7. https://doi.org/10.1093/infdis/jix063.
91. Shah K, Hilton TN, Myers L, Pinto JF, Luque AE, Hall WJ. A new frailty syndrome: central obesity and frailty in older adults with the human immunodeficiency virus. J Am Geriatr Soc. 2012;60(3):545–9. https://doi.org/10.1111/j.1532-5415.2011.03819.x.
92. Young P, Shah J, Zhang C, Ferris DC, Colon I, Bucovsky M, et al. Frailty in postmenopausal African American and Hispanic HIV-infected women. J Frailty Aging. 2016;5(4):242–6. 10.14283/jfa.2016.104.
93. Bauer LO, Wu Z, Wolfson LI. An obese body mass increases the adverse effects of HIV/AIDS on balance and gait. Phys Ther. 2011;91(7):1063–71. https://doi.org/10.2522/ptj.20100292.
94. Sharma A, Hoover DR, Shi Q, Holman S, Plankey MW, Wheeler AL, et al. Falls among middle-aged women in the Women’s Interagency HIV Study. Antivir Ther. 2016;21(8):697–706. https://doi.org/10.3851/IMP3070.
95. Shah KN, Majeed Z, Yang H, Guido JJ, Hilton TN, Polesskaya O, et al. Functional limitations and adipokines in Hiv-infected older adults. J Frailty Aging. 2015;4(1):41–6.
96. Margolick JB, Bream JH, Martinez-Maza O, Lopez J, Li X, Phair JP, et al. Frailty and circulating markers of inflammation in HIV+ and HIV- men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2017;74(4):407–17. https://doi.org/10.1097/QAI.0000000000001261.
97. Erlandson KM, Ng DK, Jacobson LP, Margolick JB, Dobs AS, Palella FJ Jr, et al. Inflammation, immune activation, Immunosenescence, and hormonal biomarkers in the frailty-related phenotype of men with or at risk for HIV infection. J Infect Dis. 2017;215(2):228–37. https://doi.org/10.1093/infdis/jiw523.
98. Schrack JA, Althoff KN, Jacobson LP, Erlandson KM, Jamieson BD, Koletar SL, et al. Accelerated longitudinal gait speed decline in HIV-infected older men. J Acquir Immune Defic Syndr. 2015;70(4):370–6. https://doi.org/10.1097/QAI.0000000000000731.
99. Schrack JA, Jacobson LP, Althoff KN, Erlandson KM, Jamieson BD, Koletar SL, et al. Effect of HIV-infection and cumulative viral load on age-related decline in grip strength. AIDS. 2016;30(17):2645–52. https://doi.org/10.1097/QAD.0000000000001245.
100. Erlandson KM, Allshouse AA, Jankowski CM, MaWhinney S, Kohrt WM, Campbell TB. Functional impairment is associated with low bone and muscle mass among persons aging with HIV infection. J Acquir Immune Defic Syndr. 2013;63(2):209–15. https://doi.org/10.1097/QAI.0b013e318289bb7e.
101. Pinto Neto LF, Sales MC, Scaramussa ES, da Paz CJ, Morelato RL. Human immunodeficiency virus infection and its association with sarcopenia. The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases. 2016;20(1):99–102. https://doi.org/10.1016/j.bjid.2015.10.003.
102. •• Lake JE, Stanley TL, Apovian CM, Bhasin S, Brown TT, Capeau J, et al. Practical review of recognition and management of obesity and lipohypertrophy in human immunodeficiency virus infection. Clin Infect Dis. 2017;64(10):1422–9. https://doi.org/10.1093/cid/cix178. This article provides a concise, up-to-date consensus statement for the clinician on the diagnosis, pathophysiology, clinical assessment and treatment of obesity and lipohypertrophy in treated HIV infection.
103. Engelson ES, Agin D, Kenya S, Werber-Zion G, Luty B, Albu JB, et al. Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism. 2006;55(10):1327–36. https://doi.org/10.1016/j.metabol.2006.05.018.
104. Terry L, Sprinz E, Stein R, Medeiros NB, Oliveira J, Ribeiro JP. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Med Sci Sports Exerc. 2006;38(3):411–7. https://doi.org/10.1249/01.mss.0000191347.73848.80.
105. Mutimura E, Crowther NJ, Cade TW, Yarasheski KE, Stewart A. Exercise training reduces central adiposity and improves metabolic indices in HAART-treated HIV-positive subjects in Rwanda: a randomized controlled trial. AIDS Res Hum Retrovir. 2008;24(1):15–23. https://doi.org/10.1089/aid.2007.0023.
106. Becofsky K, Wing EJ, McCaffery J, Bodreau M, Wing RR. A randomized, controlled trial of a behavioral weight loss program for HIV-infected patients. Clin Infect Dis. 2017; https://doi.org/10.1093/cid/cix238.
107. Reeds DN, Pietka TA, Yarasheski KE, Cade WT, Patterson BW, Okunade A, et al. HIV infection does not prevent the metabolic benefits of diet-induced weight loss in women with obesity. Obesity (Silver Spring). 2017;25(4):682–8. https://doi.org/10.1002/oby.21793.
108. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38. https://doi.org/10.1161/01.cir.0000437739.71477.ee.
109. Munro S, Dinatale E, Hartley S, St Jacques M, Oursler KA. Barriers and health beliefs related to weight management among veterans with human immunodeficiency virus. Mil Med. 2017;182(1):e1596–e602. https://doi.org/10.7205/MILMED-D-16-00086.
110. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of Pharmacological Treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424–34. https://doi.org/10.1001/jama.2016.76022528211.